Low-dose Subcutaneous Heparin in the Prevention of Deep-vein Thrombosis and Pulmonary Emboli Following Acute Stroke
Overview
Authors
Affiliations
Venous thrombo-embolism is a major and often unrecognized cause of morbidity and mortality in patients after acute strokes. Three hundred and five elderly patients were randomly allocated to either control (161) or treatment (144) with 5000 units calcium heparin subcutaneously 8-hourly for two weeks. A reduction in deep-vein thrombosis rate from 72.7% in the control group to 22.2% in treatment patients was achieved. In patients who died (84), post-mortem examination to look for pulmonary emboli was performed in 71. Comparison between treated and untreated patients showed significantly fewer deaths and pulmonary emboli in the treated group. Most of the beneficial effect on mortality was seen in patients with lighter strokes. When patients with pulmonary emboli at post-mortem were excluded, there was no significant difference in the death rate in treatment (17) and control (14) groups. At post-mortem, 9.9% of the strokes were haemorrhagic (4 in the treatment and 3 in the control group). Low-dose calcium heparin given subcutaneously following acute stroke reduced the number of deep-vein thromboses, pulmonary emboli and deaths without increasing the number of haemorrhagic strokes in this study.
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.
Moustafa B, Testai F Curr Neurol Neurosci Rep. 2022; 22(11):789-802.
PMID: 36227497 DOI: 10.1007/s11910-022-01237-z.
Eck R, Elling T, Sutton A, Wetterslev J, Gluud C, van der Horst I BMJ. 2022; 378:e070022.
PMID: 35788047 PMC: 9251634. DOI: 10.1136/bmj-2022-070022.
Anticoagulants for acute ischaemic stroke.
Wang X, Ouyang M, Yang J, Song L, Yang M, Anderson C Cochrane Database Syst Rev. 2021; 10:CD000024.
PMID: 34676532 PMC: 8530823. DOI: 10.1002/14651858.CD000024.pub5.
Dennis M, Caso V, Kappelle L, Pavlovic A, Sandercock P Eur Stroke J. 2019; 1(1):6-19.
PMID: 31008263 PMC: 6301216. DOI: 10.1177/2396987316628384.
Schunemann H, Cushman M, Burnett A, Kahn S, Beyer-Westendorf J, Spencer F Blood Adv. 2018; 2(22):3198-3225.
PMID: 30482763 PMC: 6258910. DOI: 10.1182/bloodadvances.2018022954.